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Abstract
Purpose: For high-risk prostate cancer (HR-PCa) in men with a life expectancy of at least 10 years,
the National Comprehensive Cancer Network recommends radiation therapy (RT) plus androgen
deprivation therapy (ADT) with category 1 evidence or radical prostatectomy (RP) as an accept-
able initial therapy. Randomized evidence regarding which therapy is optimal for disease control
is lacking for men with HR-PCa. We performed a propensity-score-matched comparison of out-
comes for men with localized HR-PCa treated with primary RT or RP.
Methods and materials: The medical records of patients with localized HR-PCa who were treated
at our institution between 2002 and 2011 were reviewed. Patient and disease characteristics, treat-
ment details, and outcomes were collected. A combination of nearest-neighbor propensity score
matching on age, Adult Comorbidity Evaluation-27 comorbidity index, prostate-specific antigen,
biopsy Gleason scores, and clinical T-stage as well as exact matching on prostate-specific antigen,
biopsy Gleason scores, and clinical T-stage was performed. Outcomes were measured from diag-
nosis. Multivariate Cox proportional hazards regression was used to compare metastasis-free and
overall survival.
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Results: A total of 246 patients were identified with 62 propensity-score-matched pairs. ADT was
administered to 6.5% and 80.6% of patients receiving RP and RT, respectively. Five-year rates of
metastasis for RP and RT were 33% and 8.9%, respectively (P = .003). Overall survival was not
different. Delay of salvage therapy was longer for patients undergoing primary RT (P < .001). Findings
were similar when only those patients who did not receive ADT were compared.
Conclusions: At our institution, treatment with primary RT resulted in superior metastasis-free sur-
vival over RP. This was not accompanied by an improvement in OS.
© 2017 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
High-risk prostate cancer (HR-PCa) is defined by the
National Comprehensive Cancer Center (NCCN) as ad-
enocarcinoma of the prostate with one or more of the
following high-risk features: initial prostate-specific antigen
(PSA) >20 ng/mL, clinical T stage 3a or higher, and biopsy
sum Gleason score (GS) ≥8. Despite controversy over active
treatment versus conservative management for prostate
cancer, patients with HR-PCa have a high rate of distant
metastases and 15% to 30% cancer-specific death without
primary treatment.1,2 Therefore, the relevant question for
this patient population is which primary treatment modal-
ity is the most appropriate and effective.
Per the NCCN guidelines, category 1 evidence sup-
ports the use of definitive radiation therapy (RT) plus
long-term (defined as 2-3 years) androgen deprivation
therapy (ADT). Radical prostatectomy (RP) plus pelvic
lymph node dissection is also recommended for initial
management of HR-PCa with category 2A evidence. Ran-
domized evidence comparing RP or definitive RT as the
primary treatment modality for localized prostate cancer
is limited to a few small trials that did not meet accrual
and therefore were not powered for primary endpoints
including metastasis-free survival and cause-specific
survival.3-5
The recently reported ProtecT trial randomized 1643 men
with a new diagnosis of prostate cancer and a life expec-
tancy of at least 10 years to undergo active monitoring, RP,
or RT.6 The 10-year results of the trial showed no differ-
ence in prostate cancer–specific survival with any of the
treatments and no difference in freedom from disease pro-
gression between RP or RT, which were both superior to
active monitoring. Of the men enrolled on this trial, only
2% had high-risk disease as defined by the NCCN, so it
is not clear how readily these findings can be applied to
men with HR-PCa.7
Therefore, in the absence of meaningful prospective, ran-
domized evidence, we performed a carefully matched paired
comparison of patients treated for HR-PCa at our institu-
tion per NCCN treatment guidelines for either external beam




Patients with HR-PCa as defined by the NCCN risk
grouping who received either definitive RT or RP at our
institution between 2001 and 2011 were identified. After
institutional review board approval, medical records of
these patients were reviewed for patient and disease char-
acteristics and clinical outcomes including biochemical
or clinical recurrence, development of metastatic disease,
overall survival (OS), and salvage therapy. After compari-
son of the unmatched cohorts revealed a biased distribution
of known adverse risk factors, a propensity-score-
matching algorithm was applied as described in the Statistics
section.
Survival was determined by a review of the chart and
an Internet search for confirmation of death, including pub-
lished obituaries and the social security death index. When
it could be ascertained with certainty, the cause of death
was included.
RP was either open retropubic or minimally invasive (i.e.,
laparoscopic or robotic-assisted). Lymph node dissection
was performed in all cases and commonly limited to the
obturator fossa.
Definitive RT was delivered using modern techniques
of external beam RT to a median total dose of 75.6 Gy
(range, 73.8-77.4 Gy). Intensity modulated RT was used
in 60 of 62 patients using 18 MV x-rays. Two patients re-
ceived 3-dimensional, conformal RT. Fifty-five patients were
estimated to have ≥15% risk of pelvic lymph node involve-
ment as determined by the Memorial Sloan Kettering Cancer
Center pre-radical prostatectomy nomogram and received
radiation to the pelvic lymph nodes followed by a sequen-
tial boost to the prostate. The remaining 7 patients received
radiation to the prostate and seminal vesicles followed by
a boost to the prostate. The planning target volume was de-
termined by the mode of localization and has been described
previously.8,9
ADT was administered to a proportion of patients in each
group. When delivered in conjunction with primary RT, ADT
consisted of injectable luteinizing hormone releasing
hormone administered beginning 2 months prior to the start
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of RT for a total of 2 years. Of the patients receiving upfront
RP, 1 patient received adjuvant RT, 1 patient received ad-
juvant ADT, and 3 patients received adjuvant concurrent
RT/ADT.
Statistics
A propensity-score-matching method was used to reduce
the imbalance between the RP and RT cohorts. A combi-
nation of exact matching and nearest-neighbor matching
was used. Exact matching was used on categorized primary
prostate cancer risk stratification variables, including
clinical T stage, PSA, and biopsy GS. Clinical T stage was
categorized as T1, T2, and T3. PSA was categorized as <10,
10 to 20, and ≥20. Biopsy GS was categorized as Gleason
6 or 7, Gleason 8, and Gleason >8. The variables used in
the nearest-neighbor matching process were numeric age
in years and a categorized Adult Comorbidity Evaluation-
27 (ACE-27) index score (a validated comorbidity index)10
with scores of 0, 1, and ≥2 to represent patient comorbidity.
The entire matching process was done in R, Version 3.2.2
using the package MatchIt.11 Using the date of diagnosis
as the starting time point, multivariate Cox proportional
hazards regression was used to compare metastasis-free sur-
vival, OS, and time to salvage therapy.
Results
Patient characteristics
A total of 246 patients with HR-PCa treated with
upfront RT (n = 86) or RP (n = 160) were identified. Patient
characteristics are shown in Supplemental Table S1
(available as supplementary material online only at
www.advancesradonc.org) and demonstrate an imbalance
in known adverse risk factors including clinical T stage
and present PSA in favor of RP. Therefore, we used a
propensity-score-matching approach to identify a paired
patient cohort to minimize these biases. The resulting pro-
pensity scores were well matched (Supplemental Table S2
and Supplemental Fig. S1).
As a result of the propensity-score matching, patient and
disease features including age and ACE-27 comorbidity
score were not significantly different, and initial PSA, biopsy
GleasonGS, and clinical T stage were matched exactly
(Table 1). Follow-up time and the interval from diagnosis
to the start of RT or RP were both significantly longer for
the RT group (mean: 41 vs 51.4 months [P = .004] and 56
vs 131.5 days [P < .001], respectively; Table 1). ADT was
administered as a component of initial therapy to 6.5% and
80.6% of patients receiving RP and RT, respectively. The
pathologic findings after RP are shown in Supplemental
Table S4.
Disease outcomes
Despite the more adverse features seen in patients treated
with RT in the unmatched cohort of 246 patients, distant
metastasis–free survival (DMFS) was significantly longer
(hazard ratio [HR]: 0.27; 95% confidence interval [CI], 0.10-
0.73; P = .01) and OS was not different (HR: 1.9; 95% CI,
0.83-4.32; P = .128). PSA >20 and biopsy GS of ≥8 was
also associated with worse DMFS. Additional factors that
were associated with worse OS included PSA >20 and
biopsy GS >8 (Supplemental Table S3).
For the propensity-score-matched cohort of 124 pa-
tients, DMFS was again significantly longer for patients in
the RT group compared with those in the RP group (HR:
0.023; 95% CI, 0.07-0.71; P = .011; Fig 1A). The only other
clinical factor that was significantly associated with lower
DMFS was PSA ≥20 ng/mL (Table 2). OS was not statis-
tically different between the 2 groups (HR: 1.58; 95% CI,
0.56-4.48; P = .38; Fig 1B), and no single factor was sig-
nificantly associated with OS in the Cox proportional hazards
multivariate model (Table 2). After review of the medical
charts, the cause of death was unknown for a large pro-
portion of patients and was attributed to prostate cancer for














Biopsy Gleason score NA
6 or 7 17 17
8 30 30







Standard deviation 7.1 9.1
Follow-up (months)* .004
Median 41 51.4
Standard deviation 26.5 29.8
Days to Treatment from Dx < .001
Median 56 131.5
Standard deviation 29 299
ACE-27, Adult Comorbidity Evaluation-27; Dx, diagnosis; NA, not
applicable; PSA, prostate-specific antigen; RP, radical prostatec-
tomy; RT, radiation therapy.
* Calculated from the completion of RT or date of RP.
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2 of 15 patients in the RT group and 2 of 6 patients in the
RP group. Prostate cancer–specific death could not be com-
pared given the scarcity of events. Crude biochemical failure
rates were 21% and 58% after a median of 51.4 months
and 41 months for RT and RP, respectively. Biochemical
failure was not formally compared between the treatment
groups.
Salvage therapies
Despite the worse adverse features for patients receiv-
ing RT in the unmatched cohort, salvage therapy
administration was significantly lower (HR: 0.15; 95% CI,
0.07-0.33; P < .001). Age, pretreatment PSA >20, and ACE
comorbidity score ≥2 were also associated with a higher
risk of salvage treatment (Supplemental Table S3).
For the propensity-score-matched cohort, administra-
tion of salvage therapy was 16.1% in the RT group compared
with 40.3% in the RP group (HR: 0.19; 95% CI, 0.08-
0.43; P < .001). The median time to salvage therapy for the
RT cohort was 36.3 months compared with 13.1 months
for RP. Of 8 patients receiving salvage therapy in the RT
group, 1 patient underwent salvage RP, and 7 patients re-
ceived ADT. Of patients in the RP group, salvage therapy
consisted of RT in 68% (most with concurrent ADT), ADT
alone in 24%, and chemotherapy in 8%.
Patients treated without ADT
Because of the known benefit of ADT for delay in de-
velopment of biochemical failure, development of distant
metastases. and OS, we compared the 20% of patients who
Figure 1 Propensity-score-matched outcomes. Kaplan Meier plot of (A) distant metastasis–free survival and (B) overall survival in
matched patients undergoing RP or RT for primary treatment of high-risk prostate cancer.
Table 2 Cox proportional hazards models
Metastasis free survival Overall survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
RT vs RP 0.23 0.07-0.71 .011 1.58 0.56-4.48 .385
Age 1.00 0.93-1.07 .949 1.02 0.97-1.07 .532
Clinical T Stage T2 vs T1 0.73 0.17-3.08 .667 0.44 0.12-1.65 .225
Clinical T Stage T3 vs T1 1.68 0.35-8.02 .515 0.48 0.06-4.17 .507
PSA 20+ vs <20 5.22 1.18-23.12 .029 1.47 0.51-4.27 .476
Gleason score 8 vs 6-7 2.59 0.46-14.61 .283 0.99 0.19-5.23 .995
Gleason score 8+ vs 6-7 3.53 0.66-18.96 .142 4.22 0.86-20.7 .076
ACE 1 vs 0 1.04 0.30-3.62 .956 0.70 0.19-2.6 .590
ACE 2+ vs 0 1.21 0.25-5.9 .817 2.48 0.67-9.12 .173
ACE, Adult Comorbidity Evaluation; CI, confidence interval; PSA, prostate-specific antigen; RP, radical prostatectomy; RT, radiation therapy.
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underwent RT without ADT to those who underwent RP
without ADT and found no difference in OS (P = .098) or
DM (P = .061) but a significantly lower risk of salvage
therapy for patients undergoing RT compared with RP
(P = .032; Supplemental Fig. S2).
Discussion
Selection of the best treatment option for patients with
localized HR-PCa is important not only for optimal disease
control, but also for avoiding undue therapy-related tox-
icity. In the absence of robust randomized data for these
patients, many men undergo RP for high-risk disease despite
the risk of adverse features on surgical pathology for which
the NCCN recommends consideration of adjuvant RT.12
Moreover, between 32% and 70% of patients will experi-
ence biochemical failure after RP for high-risk prostate
cancer and will thus be considered for salvage pelvic RT
if their disease remains localized.13 In our patient popula-
tion, 4 patients received adjuvant therapy and 23 patients
(37%) received salvage therapy.
Although salvage therapy after either RP or RT is thought
to be generally comparable, in any scenario, long-term
salvage rates are generally low. Stephenson et al found that
salvage RT after RP achieved 32% progression-free prob-
ability at 6 years, lower for men with pre-RT PSA of
>1 ng/mL.14 Ongoing randomized trials comparing adju-
vant RT for high-risk pathologic features to early-salvage
RT ± ADT aim to minimize the number of patients requir-
ing adjuvant RT without sacrificing disease control and
survival.15,16 With the recognition of suboptimal salvage rates,
management for HR-PCa does appear to be evolving, and
increased use of extended lymph node dissection17 and vigi-
lant post-RP surveillance with serial ultrasensitive PSA may
help improve rates of successful salvage.18
In the setting of salvage RT, efforts to improve success
include trials testing concurrent and adjuvant short-term ADT
with chemotherapy,19 pelvic lymph node RT,20 and
hypofractionated RT.21 A phase 2 study of patients with lo-
calized failure after definitive RT for HR-PCa showed a
5-year biochemical relapse-free survival and distant
metastases-free survival of 68.5% and 81.5%, respec-
tively, after salvage with prostate brachytherapy.22,23 Focal
cryotherapy showed a 2-year freedom from biochemical re-
currence for 44%,24,25 and salvage prostatectomy resulted
in approximately 45% of patients who were free from bio-
chemical recurrence at a median of 34 months.26
Perhaps as important, all salvage therapies carry addi-
tional risk for toxicity, which often compound that
experienced from the primary therapy.27,28 In our analysis,
35% of men in the RP group received 2 local therapies (5
adjuvant and 17 salvage therapy for biochemical failure)
compared with 1 patient in the RT cohort (salvage RP). If
adjuvant RT had been administered to all patients with
adverse pathologic features (≥pT3 disease, positive surgical
margins), more patients in our study would have received
adjuvant RT after RP. Toxicities from adjuvant or salvage
therapy are additive, as demonstrated with significantly more
patient-reported urinary toxicity and sexual dysfunction in
men who require RT after prostatectomy.29
Here we show that both on initial comparison and after
propensity score correction for age, clinical T stage, PSA,
GS, and a comorbidity index, the rate of distant meta-
static disease is higher in patients receiving RP as primary
therapy compared with definitive RT. The follow-up for our
cohort was relatively short (median: 5.2 years; alive without
metastases: 5.6 years), and men with prostate cancer can
experience recurrence decades after initial diagnosis.
More patients received long-term ADT as upfront therapy
with definitive RT than with RP (80.6% vs 6.5%). We pur-
posefully included patients who received ADT with RT to
represent the standard of care for HR-PCa. Similarly, most
patients who undergo RP for HR-PCa do not receive ADT
as a part of initial management. This approach was also
similar in the ProtecT trial design.7 Nevertheless, we be-
lieved it was important to remove this variable and repeated
the analysis including only patients who did not receive ADT
as part of upfront therapy. Of the 20% of patients who did
not receive ADT with RT, no patients developed meta-
static disease during the follow-up period (mean: 4.5 years
for this subgroup; range, 2.4-8.9 years).
A limitation of this study is the small sample size avail-
able for analysis. For the initial nonmatched analysis, we
included all patients with clinically HR-PCa treated at our
institution with either RP or definitive RT; thus, the analy-
sis is representative of treatment patterns at our institution.
Additionally, one might expect a decrease in the mani-
festation of metastatic disease with ADT on the order of
5% to 10% as seen in randomized trials, including Radia-
tion Therapy Oncology Group 9202.30 However, we saw
a 25% absolute lower rate of distant metastasis with RT,
with only 80% of patients receiving ADT. If ADT is indeed
responsible for the improved outcomes seen in our analy-
sis, perhaps it should be considered for more patients
undergoing RP for HR-PCa.
It is well-documented in nonrandomized settings that pa-
tients undergoing RP have less aggressive prostate cancer
features, fewer comorbid conditions, and better health than
men undergoing RT.31 In an attempt to control for pos-
sible imbalances in confounding comorbidities, we included
the ACE Comorbidity Index in our propensity score cal-
culation. Because men undergoing primary RT for prostate
cancer as a whole have significantly more comorbid con-
ditions that are expected to affect survival, we would expect
worse OS in the group undergoing RT. However, we found
that survival was not significantly different even among un-
matched patient groups (Supplemental Table S3). In the
matched comparison, although DMFS was significantly
higher in patients treated with primary RT, OS was not. Pros-
tate cancer metastases are strongly linked to prostate cancer–
specific mortality32; however, the follow-up time of this study
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is relatively short and this, along with a small sample size
and small event numbers, likely explain the lack of differ-
ence in OS.
Time from diagnosis to treatment was significantly longer
in the RT group, which highlights the path that many pa-
tients take from primary care physician to urologist and
eventually, in a proportion of patients, to a radiation on-
cologist. The connection between referral bias and treatment
decision is well documented.33 One might assume that
delayed treatment would be associated with worse out-
comes; however, we observed the opposite. Moreover, we
chose to calculate outcomes from the date of diagnosis to
development of metastatic disease, salvage treatment, and
death to account for any delay in treatment and for the in-
herent nature of RP versus RT delivered over approximately
8 weeks.
Given the retrospective nature of the study, toxicity related
to either treatment could not be reliably assessed. This is
an important consideration when comparing therapies and
should be addressed ideally in a prospective manner.
In contrast to several prior studies comparing RP with
RT for prostate cancer, the current study included contem-
porary treatment methods, with only 2 patients receiving
<75 Gy RT (dose-escalation associated with superior local
and biochemical control), 97% being treated with intensity
modulated RT, and most patients receiving long-term ADT.
Conclusions
This propensity-score-matched analysis from a single
institution using contemporary treatments corroborates prior
reports that dose-escalated RT as primary treatment for HR-
PCa is at least comparable with RP for disease control.34-36
Our data suggest that RT with concurrent/adjuvant ADT
may be superior for preventing development of distant me-
tastases. When considering the higher toxicity associated
with RP followed by either adjuvant or salvage RT and the
higher rates of salvage therapy overall, definitive dose-
escalated RT and ADT may be an overall better primary
therapy for men with high-risk prostate cancer.
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